Frencken Group Limited (SGX:E28)

Market Cap	704.70M
Revenue (ttm)	794.33M
Net Income (ttm)	37.12M
Shares Out	427.09M
EPS (ttm)	0.09
PE Ratio	19.01
Forward PE	16.79
Dividend	0.03 (1.57%)
Ex-Dividend Date	May 2, 2025

Volume	5,134,000
Average Volume	5,831,200
Open	1.650
Previous Close	1.660
Day's Range	1.630 - 1.680
52-Week Range	0.825 - 1.720
Beta	1.22
RSI	73.92
Earnings Date	Aug 14, 2025

About Revance Therapeutics

Frencken Group Limited, an investment holding company, provides original design, original equipment, and diversified integrated manufacturing solutions worldwide. The company operates in two segments, Mechatronics and Integrated Manufacturing Services (IMS). The Mechatronics segment designs, develops, and produces precision-engineered systems and machines, electromechanical assemblies, and high precision parts and components for original equipment manufacturers in the medical, semiconductor, analytical, pharmaceutical, and industrial/factory au...

• Industry: Hardware, Equipment & Parts
• Sector: Technology
• Founded: 1999
• Employees: 3,600
• Stock Exchange: Singapore Exchange
• Ticker Symbol: E28

Financial Performance

In 2024, Frencken Group's revenue was 794.33 million, an increase of 6.93% compared to the previous year's 742.86 million. Earnings were 37.12 million, an increase of 14.30%.